GSK (GSK) stock jumped back into a buy zone Monday after announcing Chief Executive Emma Walmsley will step down at the end of the year. She will be succeeded by Luke Miels, the current chief commercial officer. Prior to joining GSK in 2017, Miels has worked across the globe at AstraZeneca (AZN), Roche (RHHBY) and Sanofi (SNY). Walmsley has led GSK for nine years and says it's time to hand the reins over to someone new. "2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe t ...